Since the binding of drugs to plasma proteins can significantly after the intensity of pharmacological and toxicological effects of drugs, we studied the pharmacokinetics of three drugs in patients with hypoalbuminemia secondary to the nephrotic syndrome, but with relatively normal renal function. No significant differences were seen in the pharmacokinetic parameters observed for antipyrine, a drug which is less than 10% bound to plasms proteins. The percentage of unbound diphenylhydantoin, a highly plasms proteinbound drug, was found in patients with the nephrotic syndrome to be twice that of healthy individuals (19,2 vs. 10.1%, P smaller than 0.001). However, there was also a lower steadystate plasma concentration of diphenylhydantoin (2.9 plus or minus 0.6 vs. 6.8 plus or minus 0.6 mug/ml, P smaller than 0.001) secondary to an increase in the plasms clearance (0.048 plus or minus 0.019 vs. 0.022 plus or minus 0.006 liter/kg.h, P smaller than 0.001) in the nephrotic patients. The net effect is no difference in the absolute concentration of unbound diphenylhydantoin in healthy individuals (0.69 plus or minus 0.05 mug/ml) and patients with the nephrotic syndrome (0.59 plus or minus 0.06 mug/ml). Qualitatively, similar differences were observed with clofibrate. The dose of these drugs need not be routinely reduced in patients with the nephrotic syndrome as long as they have reasonably normal renal function (creatinine clearance […] 
INTRODUCTION
Binding of drugs to plasma proteins can profoundly influence their pharmacodynamic or toxicological actions, as well as their disposition (1) . Minor interindividual changes in the degree of binding of highly protein-bound drugs can produce significant changes in the amount of unbound drug; abnormal binding in disease states such as uremia (2, 3) and cirrhosis of the liver (4) may lead to even higher levels of unbound drug. The binding of diphenylhydantoin (DPH)' was observed to decrease as the concentration of albumin, which binds many drugs, was reduced in in vitro studies with diluted plasma (5) . The effects of reduced binding secondary to low albumin concentrations in vivo on pharmacokinetics of drugs have not been studied extensively.
Elevated concentrations of unbound drug secondary to hypoalbuminemia may be associated with increased toxicity. For example, Bridgman, Rusen, and Thorp (6) reported that five out of six patients with the nephrotic syndrome developed adverse effects to clofibrate when treated for the associated hyperlipoproteinemia. The Boston Collaborative Drug Surveillance Program (7) reported an increased incidence of toxicity from DPH in patients with hypoalbuminemia and suggested that these patients have increased circulating levels of unbound DPH.
'Abbreviations used in this paper: app Vd, apparent volume of distribution; CPIB, chlorophenoxyisobutyric acid; DPH, diphenylhydantoin; HPPH, p-hydroxyphenylphenylhydantoin; Kei, elimination rate constant; 4-OH A, 4-hy- The present work was designed to study the pharmacokinetics and metabolism of two highly proteinbound drugs, DPH and clofibrate, and of antipyrine, which is not significantly bound to plasma proteins, in patients with the nephrotic syndrome. METHODS Subjects 12 patients (9 men and 3 women) with the nephrotic syndrome and 18 healthy volunteers (14 men and 4 women) were studied (Table I) . Their ages ranged between 20 and 58 yr. Before entering the study, each subject had a complete history, physical examination, and laboratory tests which included complete blood count, urinalysis, plasma protein and protein electrophoresis, protein content of 24-h urine, creatinine clearance, bilirubin, alkaline phosphatase, and serum glutamic oxaloacetic transaminase. Written, informed consent was obtained from each volunteer after an explanation of the risks, hazards, and inconveniences reasonably to be expected.
The patients were not selected according to the etiology of their nephrotic disease; only patients with an albumin concentration in plasma equal to or less than 3 g/dl and excretion of protein in urine greater than 3 g/24 h were accepted. Individuals with creatinine clearance less than 50 ml/min or evidence of liver function impairment were arbitrarily excluded. To prevent interference with necessary treatment, patients were not taken off their current medication. Thus, patients on diuretics were accepted, but the above criteria excluded patients with marked peripheral edema. The control group was selected to match the ages of the patients with nephrosis.
Study design 10 of the 12 nephrotic patients initially received antipyrine as a single dose. Subsequently, six were given DPH and four clofibrate for 14 days. Two patients received chronic clofibrate treatment only. All patients of the DPH group in addition received a single intravenous dose of DPH at least 2 wk after completion of the chronic treatment period. Control subj ects were tested in three groups of six with one drug only; those on DPH also received the intravenous dose. A small breakfast was allowed 2 h before the single-dose studies.
Aiitipyric. 10 mg antipyrine/kg was given orally dissolved in 250 ml water after an overnight fast. 10-ml blood samples were obtained at 0, 3, 6, 9, 12, and 24 h after the dose. All urine excreted was collected in fractions Urine was collected in 24-h aliquots the final 2 days during chronic dosing and in 0-6, 6-12, 12-24, and 24-48-h fractions after the intravenous dose. Urine and blood were assayed for DPH, urine also for p-hydroxyphenylphenylhydantoin (HPPH).
Clofibrate. 1 g clofibrate (Atromid-SO, Ayerst Laboratories, New York) was given twice daily for 14 days. 10-ml blood samples were obtained just before the morning dose on days 13 and 14 and 4, 8, 12, 24, 30, 36, and 48 h after the final dose. Two 12-h urine samples were collected on day 13 . All samples were assayed for chlorophenoxyisobutyric acid (CPIB), and urine for CPIB glucuronide in addition.
Analytical procedures
Antipyrine and 4-OH A. Antipyrine was measured by a gas chromatographic method (8) with phenacetin (9) as an internal standard. 4-OH A was measured as the silylated derivative, also by gas chromatography (8) .
DPH and HPPH. DPH was assayed by a recently developed, very sensitive and highly specific radioimmunoassay (10 urine, 1 ml of 0.5 N HCl was added and the CPIB extracted into 8 ml of chloroform. After shaking and centrifuging the sample, the aqueous layer was aspirated and 7 ml of the organic layer was transferred to another tube and evaporated to dryness. The residue was dissolved in 1 ml of freshly prepared 0.5% potassium carbonate in methanol (wt/vol) and 0.1 ml dimethyl sulfate added. Methylation was achieved by heating the mixture for 10 min in a water bath at 700C. After addition of 1 ml 0.2 M acetate buffer, pH 5.6, the CPIB was extracted into 8 ml of chloroform containing 1 ,ug clofibrate/ml as an internal standard. After shaking, centrifugation, and aspiration of the aqueous phase, 7 ml of the organic phase was transferred into conical tubes and evaporated under a gentle stream of air to a volume of 0.1-0.2 ml. Evaporation should not be done in a water bath even at room temperature since the cooling temperature produced during evaporation is essential to prevent hydrolysis of clofibrate. Gas chromatographic analysis was performed by injecting 1-3 Al onto a 6-ft column packed with 3% SE30 on G.A.S.-Chrom Q (80-100 mesh, Applied Science Labs, Inc., State College, Pa.) in a BarberColman 5000 gas chromatograph (Barber-Colman Company, Rockford, Ill.). The temperature of the oven was 1850C, the injection port 2400C, and the flame ionization detector 2700 C. Retention times of CPIB and clofibrate were 2.0 and 2.5 min, respectively. Concentrations as low as 3 Ag/ml were easily detectable. Recovery of CPIB was 94±2%.
CPIB glucuronide was measured as CPIB after enzymatic hydrolysis of urine samples diluted 1: 10 with 0.1 M acetate buffer, pH 5.0. 0.1 ml (20,000 Fishman U) p-glucuronidase-sulfatase solution from Helix pornatia (Sigma Chemical Co., St. Louis, Mo.) was added to 4 ml diluted urine and incubated for 12 h at 37'C.
During validation of our analytical procedures we noted poor recovery due to inadequate hydrolysis of all the above metabolites added to the urine of nephrotic patients. If the urine were boiled for Fig. 2 . Protein binding was significantly reduced (P < 0.001) from a mean of 89.9 to 80.8c, resulting in a doubling of the fraction of unbound drug. However, the concentration of unbound DPH was not different in the nephrotic patients (0.59±0.06 Mg/ml) and controls (0.69± 0.05 mg/ml). An inverse correlation between the albumin concentration in plasma and the percentage of unbound drug was found for the nephrotic patients and the controls (Fig. 3) , the correlation coefficient being 0.96 (P < 0.01).
The t; of DPH was decreased in nephrotic patients. but this difference failed to reach statistical significance (t = 2.19; v = 10). due in part to a large variation between individuals. The plasma clearance, obtained from the single intravenous studies, of 0.048+ 0.019 in the nephrotic patients compared to 0.022± 0.006 liters/kg h in controls was significantly different (P < 0.005).
The steady-state plasma concentration following treatment with 300 mg of DPH for 14 days was 2.9±0.6 Ag/ml in the patients, whereas control subjects had 6.8±1.6 fg/ml. 1 g clofibrate twice daily, an inverse correlation was found between body weight and the steady-state plasma concentration (Fig. 5) . The steady-state concentration of CPIB in several hyperlipoproteinemic patients from our clinic on the same dose is also included in the figure. Similar parameters of the nephrotic patients were clearly below the regression line (Fig. 5 ). When viewed as individual patients in this manner, the pronounced difference is more obvious than from the cumulated data. The excretion of CPIB and CPIB glucuronide in urine is recorded in Table III . No significant difference was found between nephrotic patients and the controls in the excretion in urine of either CPIB, CPIB glucuronide, steady state.
Pharmacokinetics of Drugs in Patients with the Nephrotic Syndrome
or CPIB/CPIB glucuronide ratio in the DISCUSSION It is well recognized that in uremic patients DPH steady-state concentrations are lower than in normal volunteers (2, 13, 14) . The decreased binding in this disease appears to be related to inherent alteration in the plasma proteins (3) whereas a change in the protein concentration per se seems to be of minor importance (2) . Therefore, we deemed it necessary to study nephrotic patients without uremia to exclude possible changes in protein binding and metabolism caused by severe renal failure. \We arbitrarily excluded individuals with a creatinine clearance less than 50 ml,/'Thin. The majority of the patients studied were also receiving additional drug therapy, mostly diuretics (Table I). Of the drugs given, however, only spironolactone is known to be an agent that induces hepatic microsomal drug oxidation (15) . Furosemide is considerably bound to plasma proteins and some displacement of DPH and CPIB from their binding sites by this drug cannot be excluded, although a significant effect is rather unlikely considering the doses used and the short half-life of furosemide ('16) . In addition, we have found no displacement of DPH (6 jug/ml) from protein binding sites in the presence of furosemide (6 The decreased steady-state concentration in nephrotic patients receiving DPH appears to be due to a consistent increase in app Vd, the Kei being higher although not statistically significant due to the large interpatient variation. In patients receiving clofibrate, the increased rate of elimination appears to be a major mechanism responsible for the decreased steady-state levels. Since an intravenous dosage form is not available, the contribution of changes in app Vd could not be ascertained. The excretion of antipyrine, DPH, and CPIB in urine did not vary in nephrotic patients from the controls. These drugs, however, are extensively metabolized in man. It would be of interest to study a drug which is highly protein bound and excreted primarily unchanged to determine whether loss of large amounts of protein in urine increases the excretion of the drug in the urine.
Since the concentration of unbound drug in nephrotic patients is not different from that found in healthy subjects, modification of the dose of highly bound acidic drugs such as DPH and clofibrate is not necessary. This statement seems to be in contradiction to the reports on increased toxicity from DPH in patients with low albumin concentration (7) and from clofibrate in patients with the nephrotic syndrome (6) . The Boston Collaborative Drug Surveillance Program study (7) includes all hypoalbuminemic patients without regard for the underlying disease. Although the authors state there was no evidence the results were due to a preponderance of patients with chronic liver disease, the numbers in each group were rather small. If the liver disease is significant, the majority of these individuals would have impairment of drug metabolism with resulting high rather than low steady-state drug levels. Similarly, all but one of the nephrotic patients described by Bridgman et al. (6) had a severe reduction in renal function with serum creatinine concentrations higher than 4 mg/dl. We find that uremic patients (creatinine clearance < 20 ml/min) have a decreased Kei of CPIB caused by a reduction in the rate of metabolism of the drug.' The toxicity seen in nephrotic patients with severely compromised renal function is, therefore, most likely due to an increased concentration of unbound CPIB secondary to one or more of three abnormalities: (a) decreased levels of albumin; (b) increased concentrations of unbound acidic drugs associated with the abnormal albumin from uremic patients; and (c) decreased Kei producing elevated total CPIB levels in plasma.
In those nephrotic individuals with impaired renal function (creatinine clearance < 20 ml/min) the dose of clofibrate should be adjusted downward whereas no change is necessary in those with relatively normal renal function. The nephrotic syndrome is associated with hyperlipidemia which appears to be significantly related to the increased incidence of the coronary heart disease observed in patients with this disorder (18) . Therefore, our observations take on even greater importance in view of the tendency of physicians to treat the hyperlipidemia of the nephrotic syndrome with clofibrate. It is axiomatic among pharmacologists that both effect and toxicity are better related to the level of unbound drug in plasma than to total level, dose, or body burden. Proof of this concept has been obtained for sulfonamides (19) . Although in individuals with normal protein binding the concentration of total DPH in plasma correlates with antiepileptic activity, adequate effect has been reported in newborns and uremic individuals at very low levels and is thought due to an increased concentration of unbound DPH (20) . The adverse effects of DPH similarly correlate best with the level of unbound DPH (21) . With all highly bound acidic drugs, knowledge of the concentration of unbound drug is essential to the proper interpretation of total blood levels and subsequent treatment of the patient.
